MetaCap

Telix Pharmaceuticals Balance Sheet

NASDAQ: TLXHealth CareBiotechnology: Pharmaceutical PreparationsUSD

11.21+0.20 (+1.82%)

At close: Oct 9, 4:00 PM ET · Delayed 15 min

Telix Pharmaceuticals financial position

At the end of fiscal 2025, Telix Pharmaceuticals reported total assets of $1.16 billion, up 23.8% from a year earlier against total liabilities of $748.6 million. Shareholders' equity stood at $415.4 million, or 35.7% of assets. The company held $141.9 million in cash and equivalents against $405.0 million of debt, a net debt position of $263.2 million.

The current ratio (current assets divided by current liabilities) was 1.43, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.98.

Summary generated from market data by MetaCap's automated system. Methodology

Telix Pharmaceuticals balance sheet (annual)

Telix Pharmaceuticals annual balance sheet
Fiscal year (USD)FY 20252025-12-31FY 20242024-12-31FY 20232023-12-31
Cash & Equivalents141.87M440.00M84.30M
Receivables129.20M86.93M44.04M
Inventory37.08M23.62M12.74M
Total Current Assets330.28M570.12M158.69M
Property, Plant & Equipment58.66M27.84M15.85M
Goodwill198.99M66.59M—
Intangible Assets592.82M257.86M—
Total Assets1.16B940.38M277.26M
Accounts Payable150.35M86.79M54.33M
Short-Term Debt13.11M11.76M660.00K
Total Current Liabilities231.62M205.09M111.37M
Long-Term Debt391.91M341.81M5.95M
Total Liabilities748.61M587.44M174.61M
Shareholders' Equity415.38M352.94M102.64M
Retained Earnings-154.54M-152.91M-187.12M
Total Debt405.02M353.57M6.61M
Net Cash (Debt)-263.16M86.42M77.69M

This table shows 3 annual periods of Telix Pharmaceuticals's balance sheet, from FY 2025 back to FY 2023, across 17 line items including cash & equivalents, receivables, inventory. Values in USD; B = billions, M = millions. Fiscal periods follow TLX's reporting calendar. What is a balance sheet?

More financial data